Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
215.48
-0.64 (-0.30%)
Aug 7, 2026, 12:48 PM EDT - Market open

Alnylam Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
4,8043,7142,2481,8281,037844.29
Revenue Growth
95.14%65.19%22.97%76.23%22.88%71.31%
Gross Profit
3,8273,0321,9251,518868.6704.14
Operating Income
999.78501.58-176.89-282.18-785.07-708.65
Net Income
807.99313.75-278.16-440.24-1,131-852.82
Earnings Per Share
5.382.33-2.18-3.52-9.30-7.20
EPS Growth
------

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
AMVUTTRA
3,4142,314970.45557.8493.8-
ONPATTRO
109.7172.79252.86354.55557.61474.74
GIVLAARI
324.83308.49255.87219.25173.14127.82
OXLUMO
205.92191.44167.05109.8469.7859.59
Roche - Collaboration
437.09394.88119.49337.8--
Regeneron Pharmaceuticals - Collaboration
81.73113.96302.8100.4787.84113.23
Novartis AG - Collaboration
--79.7686.7343.1649.12
Other - Collaboration
3.1144.538.1821.193.9118.61
Royalty
228.22174.0291.7940.638.181.2
Revenue (Total)
4,8043,7142,2481,8281,037844.29

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
3,3082,9082,6952,4392,1922,436
Total Debt
1,2671,2781,2961,3051,320997.59
Net Cash (Debt)
2,0411,6301,3981,134872.161,438
Net Cash Growth
30.77%16.56%23.32%30.02%-39.35%6.26%
Net Cash Per Share
14.8412.1010.969.087.1712.14

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
885.89524.08-8.31104.16-541.27-641.69
Capital Expenditures
-91.95-58.7-34.28-62.21-72.06-76.37
Free Cash Flow
793.95465.38-42.5941.95-613.33-718.07
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
79.65%81.64%85.62%83.02%83.73%83.40%
Operating Margin
20.81%13.51%-7.87%-15.43%-75.68%-83.94%
Pretax Margin
16.64%8.70%-16.79%-23.71%-108.63%-100.93%
Profit Margin
16.82%8.45%-12.37%-24.08%-109.04%-101.01%
FCF Margin
16.53%12.53%-1.89%2.29%-59.12%-85.05%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
38.46170.67----
Forward PE
25.1660.03----
P/FCF Ratio
35.27113.11-574.04--
PS Ratio
6.0214.1713.5313.1728.3924.14